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Objectives: Current research efforts are centered on delineating the novel health benefits of naturally derived
saccharides, including growing interest in their abilities to influence neurologic health. We performed a
comprehensive review of the literature to consolidate all controlled studies assessing various roles of
exogenous saccharide compounds and polysaccharide-rich extracts from plants, fungi, and other natural
sources on brain function, with a significant focus on benefits derived from oral intake.
Methods: Studies were identified by conducting electronic searches on PubMed and Google Scholar.
Reference lists of articles were also reviewed for additional relevant studies. Only articles published in
English were included in this review.
Results: Six randomized, double-blind, placebo-controlled clinical studies were identified in which
consumption of a blend of plant-derived polysaccharides showed positive effects on cognitive function
and mood in healthy adults. A separate controlled clinical study observed improvements in well-being with
ingestion of a yeast beta-glucan. Numerous animal and in vitro studies have demonstrated the ability of
individual saccharide compounds and polysaccharide-rich extracts to modify behavior, enhance synaptic
plasticity, and provide neuroprotective effects.
Discussion: Although the mechanisms by which exogenous saccharides can influence brain function are not
well understood at this time, the literature suggests that certain naturally occurring compounds and
polysaccharide-rich extracts show promise, when taken orally, in supporting neurologic health and
function. Additional well-controlled clinical studies on larger populations are necessary, however, before
specific recommendations can be made.
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Introduction
The increasing prevalence of debilitating neurodeve-
lopmental, psychiatric, and neurodegenerative dis-
eases continues to be of significant concern for the
developed world.
1 Owing to the paucity of affordable,
safe, and effective treatment options for neurologic
disorders, there is considerable interest in preventative
and therapeutic complementary and alternative medi-
cines. According to a recent survey, 21% of American
adults with common neurologic conditions (memory
loss, back pain with sciatica, migraines, regular head-
aches, seizures, stroke, and dementia) use biologically
based therapies, consisting primarily of herbal reme-
dies.
2 Traditional Chinese, Ayurvedic, and African
medicines have utilized an assortment of plants and
herbal extracts to treat various central nervous system
(CNS) dysfunctions.
3 Effective compounds from well-
known neurobiologically active plants include flavo-
noids from Gingko biloba and Hypericum perforatum
(St John’s wort) as well as alkaloids, quinones,
tannins, and other phenolic compounds. To date, very
little attention has been given, however, to exploring
the efficacy of naturally derived complex carbohydrate
compounds. (For the sake of this review, the term
complex carbohydrates will be used interchangeably
with the terms glycans, polysaccharides, fiber, and
complex sugars or saccharides.)
Saccharide molecules play a number of fundamen-
tally important roles in the brain, where they are
largely glycoconjugated to proteins or lipids to assist
in structural development, synaptogenesis, and
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4 Saccharides can also be used as
a source for energy and neurotransmitter production.
5
An early review highlighted the potential role and
impact of saccharides in both simple and complex gly-
coconjugated form for supporting brain and cognitive
function.
6 Indeed, exogenouslyapplied small sugar mol-
ecules, specifically monosaccharides, have been shown
to impact functions within the brain related to cognitive
benefits in human and animal studies. For example,
consumption of glucose, a monosaccharide with well-
established effects on brain function, has significant
impacts on mood and cognition in human subjects.
7
Systemic and intracranial application of L-fucose have
been shown to influence glycoprotein synthesis and
enhance memory behavior and synaptic plasticity in
rodents,
8,9 whereas sialic acid, another monosaccharide
component of glycoproteins, has been shown to improve
learning and memory following oral administration to
piglets.
10 Given the high concentrations of sialic acid
in both the brain and human breast milk, it has been
hypothesized that this monosaccharide may be an
important nutrient for infant brain development.
11
The exogenous application of more complex sugar
compounds has also been studied with respect to
impacts on the brain. However, there remains a
limited understanding of the potential mechanisms
by which complex saccharide molecules may be influ-
encing neurologic function. Saccharides derived from
natural sources are structurally heterogeneous, come
in neutral and acidic varieties, and can contain as
much as 10 different monosaccharide sugars. The
diversity of saccharides in both form and source pro-
vides potential for applied research into the occur-
rence, structure, and health properties of saccharides.
In particular, varieties of saccharide compounds
have been shown to improve brain function in vitro
and in human and animal studies following oral, sys-
temic, and localized administration. To better under-
stand the efficacy and possible mechanisms of action
by which complex saccharides influence CNS func-
tion, we thus conducted this review of the available lit-
erature. It is anticipated that this information may be
useful for guiding future research that will eventually
provide a clear understanding of safe and effective
dietary complex saccharides for specific neurologic
health applications.
Dietary polysaccharides improve cognitive
function and mood in healthy young and
middle-aged adults
A number of preliminary randomized, double-blind,
placebo-controlled clinical trials have indicated that
consumption of naturally sourced polysaccharides
can benefit brain function in healthy young and
middle-aged adults (Table 1). Supplementation with
a baker’s yeast beta-glucan product (Wellmune
WGP
®; Biothera, Eagan, MN, USA) for 4 weeks
improved various measures of well-being in healthy
adult marathon runners compared with placebo.
12
Specifically, profile of mood state scores of tension,
fatigue, anger, and confusion were significantly
decreased and scores of vigor were significantly
increased following supplementation. Significant
improvements in cognitive function and mood have
also been found in healthy middle-aged adults with
a mixed polysaccharide product (Ambrotose
®
complex; Mannatech, Incorporated, Coppell, TX,
USA). In a recent study, individuals supplemented
their diets for 12 weeks with placebo or a blend of sac-
charide-rich extracts from plants including Aloe vera,
Astragalus gummifer, and Anogeissus latifolia.W h e n
compared with placebo, those subjects who consumed
the blend of plant polysaccharides performed signifi-
cantly better on tasks of recall and recognition
memory and reported significantly reduced scores for
tension and low mood (depression-dejection scale).
13
Interestingly, acute effects on brain function have
also been observed following intake of plant polysac-
charides. A single dose of Ambrotose
® complex admi-
nistered to healthy, middle-aged adults has been
recently shown to improve recognition memory and
working memory despite conditions of mental
fatigue.
14 In this study, blood glucose-mediated
effects on cognitive function were ruled out since no
changes in blood glucose levels were observed before
or during testing, at 30 and 105 minutes post-treat-
ment, respectively. Earlier research in middle-aged
adults showed that a single dose of Ambrotose
®
complex had a tendency towards positive effects on
memory tasks; however, these differences were not
statistically significant, which may have been due to
methodological differences in dose and time between
supplementation and testing (10 minutes).
15 Two
studies of young adults demonstrated improved per-
formance on tasks of visual discrimination and
working memory at 45 minutes following intake of
Ambrotose
® complex.
16 The exact mechanisms of
action behind these acute improvements in cognitive
function and mood are unclear. However, in a separate
study of young male adults, significant increases in
electroencephalogram-recorded brain wave frequen-
cies during focused attention were seen 30 minutes
after consumption of Ambrotose
® complex relative
to placebo.
17 The specific changes in brain wave fre-
quencies observed are commonly associated with abil-
ities such as concentration and arousal. Overall,
supplementation with a blend of plant polysaccharides
seems to benefit various aspects of neurologic function
and suggests functional benefits in healthy young and
middle-aged adults. It is important to note, however,
that these clinical studies, although well-controlled,
were performed on relatively small populations;
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Polysaccharide(s)
(product name) Source(s) Study design Population N Dose Duration Cognitive tests performed Significant effects Reference
Beta-1,3/1,6 glucan
(Wellmune WGP
®)
Saccharomyces
cerevisiae
Randomized,
double-blind,
placebo-
controlled
Healthy adult
marathon
runners
75 250 or 500 mg/
day
4 weeks POMS 250 mg reduced tension and
fatigue scores at 4 weeks
and reduced confusion
scores at 2 and 4 weeks;
500 mg reduced anger
scores at 2 weeks, reduced
fatigue, tension and
confusion scores at 2 and 4
weeks and increased vigor
scores at 2 and 4 weeks
12
Mixed polysaccharide
product
(Ambrotose
®
complex)
Aloe
barbadensis,
Larix sp.,
Anogeissus
latifolia,
Astragalus
gummifer,
Oryza sativa,
glucosamine
HCl
Randomized,
double-blind,
placebo-
controlled
Healthy, middle-
aged adults
109 3.6 g/day 12 weeks RAVLT; Visual Pattern Span
Recall; Visual Pattern Span
Recognition Reading Span;
Computation Span; Stroop;
Letter Cancellation; Digit
Symbol Coding, Boxes test,
Matrix Reasoning & Spot
the Word (Weschler Adult
Intelligence Scale III);
POMS; Depression Anxiety
and Stress Scale;
Perceived Stress Scale-10
Better performance on
immediate recall tasks
[RAVLT trials 2 and 5] and
recognition memory task
[RAVLT Recognition]; lower
depression-dejection and
anger-hostility scores
[POMS]
13
73 4 g 2 hours RAVLT; Cognitive Demand
battery (Serial Threes;
Serial Sevens, Rapid Visual
Information Processing,
Visual analog mental
fatigue scale); POMS;
Short-form health survey
(SF-36); State-trait anxiety
questionnaire; Bond–Lader
visual analog scale
Better performance on
recognition memory task
[RAVLT recognition A & B]
and working memory task
[Serial Sevens] during
mental fatigue. Effects were
independent of blood
glucose response
14
45 7 g 10 minutes RAVLT; Self-Ordered Pointing;
Digit Span forwards; Digit
Span backwards; Matrix
Reasoning (Weschler Adult
Intelligence Scale III)
No effects. 25 g glucose also
showed no effects
15
Continued
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1larger study groups are needed to confirm the validity
of these results.
Exogenous saccharides modulate memory- and
mood-related behaviors in rodents
Given the mechanistic limitations associated with
clinical research, rodent models are commonly utilized
to study the effects of therapeutic interventions on the
CNS. A variety of rodent behavioral tests can be sig-
nificant indicators of human cognitive function,
which, when combined with experimentation on
tissues from specific brain regions, can help elucidate
possible mechanisms of action. For studies looking
at behavioral and neurobiological effects of natural
saccharides, animals with neurologic impairments
have been utilized, which serves to both study the effi-
cacy for protection against impairment-induced func-
tional deficits and increase the likelihood of
observing positive results (Table 2). For example,
oral administration of isolichenan, an alpha-glucan
from the lichen Cetrariella islandica, to ethanol-fed
mice was able to reverse the ethanol-induced impair-
ment in memory acquisition assessed by passive avoid-
ance tests.
18 Furthermore, an attenuation of spatial
memory deficits during testing in the Morris water
maze were observed with isolichenan ingestion in rats
exposed to beta-amyloid peptide (A-beta), a small
protein associated with the neurologic deterioration
of Alzheimer’s disease. It is important to note that in
both studies, naive animals – those unexposed to
either ethanol or A-beta – did not display memory
enhancements with isolichenan treatment.
A recent study looking at the effects of dietary fiber
on sickness behavior demonstrated faster recovery
from lipopolysaccharide (LPS)-induced social with-
drawal with a pectin diet compared with a cellulose
diet.
19 Although cellulose also falls within the
complex saccharide category, this study was concerned
with comparing the immunological benefits of soluble
(pectin) versus insoluble (cellulose) dietary fiber. Their
results suggest that effects within the gastrointestinal
tract following consumption of soluble, fermentable
carbohydrates may be important for the neuroimmune
recovery from LPS. Gastrointestinal fermentation
effects were also proposed as one possible mechanism
by which orally administered arabinoxylan from the
yeast Triticum aestivum and beta-glucan from barley
were able to preserve memory in a mouse model of
vascular dementia.
20
Neurologic effects of polysaccharide-rich plant
extracts have also been observed in rodents following
systemic injection (Table 2). The biological activity
of Asian ginseng (Panax ginseng), a traditional
Chinese medicine and popular natural product with
touted cognitive health benefits, is typically attributed
to its ginsenoside saponin content.
21 However, some
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Polysaccharide(s) Source(s) Animals Dose/day Duration CNS tests performed Significant effects Reference
Alpha-glucan
(isolichenan)
Cetrariella
islandica
5-week-old ♂ Std-
ddY mice treated
with 30% ethanol
p.o. 20 minutes
before learning
trial
100, 200, or
400 mg/kg
p.o. once
30 minutes
before
learning trial
Passive avoidance step
through and step down
All doses reversed ethanol
impaired fear memory
acquisition; no effects on mice
without ethanol exposure
18
♂ Wistar rats
receiving daily
i.c.v. injections of
A-beta peptide
from day 7 to
day 4
100 or 200 mg/
kg p.o.
8 days Morris water maze 100 mg/kg reversed A-beta-
induced spatial memory
deficits; no effects on rats
without A-beta peptide
pretreatment
18
Arabinoxylan; beta-
glucan
Triticum
aestivum L.;
Hordeum
vulgare L.
♂ Sprague–Dawley
rats with bilateral
common carotid
artery occlusion
20 mg/kg p.o. Days 8–14 post-
surgery;
testing on
days 22–26
post-surgery
Morris water maze;
immunohistochemistry
and western blot (GFAP,
MBP); Luxol fast blue
and hematoxylin
staining
Both treatments reversed
ischemia-induced spatial
memory deficits; arabinoxylan
prevented loss of MBP in
corpus callosum
20
Pectin Citrus [peel] 9–11-week-old
C56BL/6J mice
injected i.p. with
100 μg/kg LPS
10% pectin diet 6–8 weeks post-
weaning
Social exploratory
behavior of a novel
juvenile mouse
Faster recovery from LPS-
induced social withdrawal
compared with 5% cellulose
diet
19
Polysaccharide
fraction: PSF (no
characterization
provided)
Panax ginseng Adult ♂ Wistar rats 4, 20, or 40 mg/
kg i.p.
10 days Conditioned Active
Escape Response
All doses differentially improved
indications of learning and
memory
22
Alpha-glucan (FPS) Fu Zi (Aconitum
carmichaeli
Debx)
8–11-week-old ♂
C57BL/6 mice
5 to 400 mg/kg
i.p.
Varied with
assay: 30
minutes, 6
hours, or 1–4
weeks
BrdU labeling; forced
swim; open-field;
novelty-suppressed
feeding; chronic social
defeat stress;
monoamine levels in the
frontal cortex; ELISA
and Western blot
(BDNF)
10–400 mg/kg doses increased
newborn neurons in the DG; 50
and 100 mg/kg produced AD
effects (similar to imipramine);
100 mg/kg increased BDNF
expression in the
hippocampus; AD and
neurogenesis effects were
blocked by co-injection with
K252a (trkB inhibitor)
23
AD, antidepressant; BrdU, 5-bromo-2′-deoxyuridine; DG, dentate gyrus; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillary acidic protein; i.c.v., intracerebroventricular injection; i.p.,
intraperitoneal injection; MBP, myelin basic protein; p.o., oral administration.
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3research suggests that ginseng’s saccharide com-
ponents may also play a role. A polysaccharide
fraction of P. ginseng administered by daily intraperi-
toneal injections for 10 days seemed to enhance learn-
ing in healthy adult rats.
22 Possible mechanisms of
action were not addressed by the authors of this
study. Fu Zi, a preparation of the daughter root
from the plant Aconitum carmichaeli Debeaux
(Chinese Monkshood), is another traditional Chinese
medicine that has been used for centuries to treat
mood disorders. Intraperitoneal injections of an
alpha-glucan isolated from Fu Zi (FPS) showed anti-
depressant-like effects in the forced swim test, similar
to the tricyclic antidepressant imipramine, in healthy
mice.
23 Surprisingly, FPS was also able to reverse the
social avoidance behavior of defeated mice, a model
of chronic stress, within just 2 weeks of intraperitoneal
administration, whereas the effects of imipramine
treatment were only observed after 4 weeks. The
authors attributed these behavioral effects to increased
brain-derived neurotrophic factor (BDNF) signaling
and neurogenesis within the hippocampus, both
known to be associated with an antidepressant-like
response.
24
Alpha- and beta-glucans enhance hippocampal
synaptic plasticity
The hippocampus is an important brain structure
that helps regulate many behaviors, including
memory and mood, and contains one of only a few
sites of adult neurogenesis, the dentate gyrus. Owing
to its organized neuronal circuitry, the hippocampus
is commonly utilized to measure various types of
synaptic transmission, including a form of synaptic
plasticity – long-term potentiation (LTP) – that is
believed to be the cellular basis for learning and
memory. LTP is observed as an activity-dependent
increase in synaptic strength that takes place when
repeated presynaptic neurotransmitter release immedi-
ately precedes the generation of an action potential by
the postsynaptic neuron, rendering the postsynaptic
neuron hypersensitive to subsequent stimulation. It
is thought that this repeated stimulation represents
learning during exposure to a novel stimulus, which
then strengthens specific synaptic connections for
encoding long-term memories. Some of the first in
vivo electrophysiological recordings of LTP, performed
on anesthetized rabbits, were of the responses of
hippocampal dentate gyrus neurons receiving synaptic
inputs from the entorhinal cortex.
25
Utilizing a similar method of recording hippocam-
pal LTP in rats, a number of studies have found signifi-
cant effects of lichen- and fungal-derived glucans on
synaptic plasticity (Table 3). Acute exposure (≤30
minutes) to the alpha-glucans PC-2 and PB-2 from
the lichens Parmelia caperata and Flavoparmelia
baltimorensis, respectively, enhanced the magnitude
of LTP induction when administered either orally or
intravenously.
26,27 Intravenous administration of
another lichen-derived alpha-glucan, isolichenan
from Cetariella islandica, also enhanced synaptic plas-
ticity in the dentate gyrus.
18 In this case, these results
correlated somewhat with isolichenan’s ability to
reduce memory impairments following oral adminis-
tration (see Table 2). Interestingly, although the
effects of PB-2 and PC-2 on synaptic plasticity were
seen with both oral and intravenous administration,
no changes were seen when the alpha-glucans were
applied directly to the brain via intracranial ventricu-
lar injection. Owing to these results, the authors pro-
posed a peripheral site of action for alpha-glucans,
which then leads to unidentified centralized signaling
mechanism(s) that can elicit the observed effects on
synaptic activity. Additional studies suggest an invol-
vement of norepinephrine, both centrally and periph-
erally. Co-intravenous injection or pretreatment with
specific beta-1-adrenergic receptor antagonists, by
either intracranial ventricular injection or direct infu-
sion into the dentate gyrus, resulted in inhibition of
PB-2’s ability to enhance LTP.
28,29 These findings are
further supported by the observation that PC-2 had
no effects on synaptic plasticity in adrenalectomized
rats.
26 Activation of brain interleukin-1 receptors
(IL-1R) may also play a role, since intracranial ventri-
cular injection of IL-1R antagonist prior to intrave-
nous PB-2 application was shown to enhance the
alpha-glucan’s effects on LTP.
28
Like alpha-glucans, beta-glucans also appear to
modulate synaptic plasticity (Table 3). Oral and intra-
venous administration of lentinan, a beta-1,3/1,6
glucan from the fungus Lentinula edodes, and oral
administration of Hoelen, a beta-glucan from the
fungus Poria cocos Wolf, resulted in increased magni-
tudes of LTP.
30,31 Altogether, there is a fair amount of
in vivo evidence suggesting alpha- and beta-glucan
consumption can lead to positive effects on synaptic
activity in the dentate gyrus of the hippocampus.
Additional research is needed to determine whether
these saccharide-induced changes in synaptic plasticity
convincingly lead to cognitive outcomes, and whether
these functional and behavioral effects are mediated
by norepinephrine or IL-1 receptor activation in the
hippocampus.
Neuroprotective effects of plant-derived
saccharides
Neurodegenerative diseases, including Alzheimer’s,
Parkinson’s, and Huntington’s, are devastating dis-
orders that result from progressive loss of neurons in
various brain regions that control motor and cognitive
function. Aging is the greatest risk factor for these dis-
eases. Identifying treatments to prevent neuronal loss
Nelson et al. Neurologic effects of exogenous saccharides
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Polysaccharide(s) Source(s) Animals Dose LTP protocol Significant effects Reference
Alpha-glucan (PC-2) Parmelia caperata Anesthetized 7–8-week-old ♂
Wistar rats
125 or 250 mg/
kg p.o.
30 minutes before weak
tetanic stimulation (20
pulses at 60 Hz)
250 mg/kg enhanced the magnitude of LTP for up to 40
minutes
26
Anesthetized 7–8-week-old ♂
normal and adrenolectomized
Wistar rats
0.1–5m g /kg i.v. 15 minutes before weak
tetanic stimulation (20
pulses at 60 Hz)
1m g /kg enhanced the magnitude of LTP induction in normal
but not adrenolectomized rats
26
Anesthetized 7–8-week-old ♂
normal Wistar rats
10–1000 ng
i.c.v.
Not provided LTP unchanged (data not shown) 26
Alpha-glucan (PB-2) Flavoparmelia
baltimorensis
Anesthetized 5–6-week-old ♂
Wistar/ST rats
50, 100, or
200 mg/kg
p.o.
20 minutes before weak
tetanic stimulation (30
pulses at 60 Hz)
100 and 200 mg/kg enhanced the magnitude of LTP induction 27
0.1–10 mg/kg
i.v.
20 minutes before weak
tetanic stimulation (30
pulses at 60 Hz)
1 and 5 mg/kg enhanced the magnitude of LTP induction 27
1o r2μg/brain
i.c.v.
20 minutes before weak
tetanic stimulation (30
pulses at 60 Hz)
LTP unchanged 27
Anesthetized 6–9-week-old ♂
Wistar rats
5.0 mg/kg i.v. 15 minutes before weak
tetanic stimulation (30
pulses at 60 Hz)
Enhanced the magnitude of LTP induction. This effect was
blocked by i.v., i.c.v. or DG injections of atenolol (adrenergic
beta-1 receptor antagonist)
29
Anesthetized 5–8-week-old ♂
Wistar rats
1.0 mg/kg i.v. 15 minutes before weak
tetanic stimulation (30
pulses at 60 Hz)
Enhanced the magnitude of LTP induction. This effect was
further enhanced by i.v. or i.c.v. injections of IL-1Ra and
inhibited by i.c.v. metropolol (adrenergic beta-1 receptor
antagonist)
28
Alpha-glucan
(isolichenan)
Cetrariella
islandica
Anesthetized ♂ Wistar rats 1 mg/kg i.v. 15 minutes before weak
tetanic stimulation (20
pulses at 60 Hz)
Enhanced the magnitude of LTP induction 18
Beta-1,3/1,6 glucan
(lentinan)
Lentinula edodes Anesthetized 7–8-week-old ♂
Wistar rats
200 mg/kg p.o. 30 minutes before weak
tetanic stimulation (20
pulses at 60 Hz)
Enhanced the magnitude of LTP induction 30
1m g /kg i.v. 15 minutes before weak
tetanic stimulation (20
pulses at 60 Hz)
Enhanced the magnitude of LTP induction 30
DG, dentate gyrus; i.c.v., intracerebroventricular injection; i.v., intravenous injection; p.o., oral administration.
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5has proven a daunting task, and as the average life
expectancy of the human population continues to
increase, the need for successful therapies intensifies.
An encouraging number of animal and in vitro
studies have demonstrated neuroprotective effects of
plant-derived saccharides and saccharide-rich extracts
(Table 4).
Effects of the disaccharide trehalose, found in
baker’s yeast, have been studied in a mouse model of
Huntington’s disease, R6/2 transgenic mice.
Following oral administration for 12 weeks, trehalose
improved motor dysfunction and reduced brain
atrophy and the number of ubiquitin-positive aggre-
gates in the motor cortex and striatum.
32 A compara-
tive glucose feeding was found to be ineffective,
leading the authors to conclude that the beneficial
activities of trehalose could be attributed to the treha-
lose molecule itself and not to its glucose subunits.
Indeed, trehalose was found in measurable amounts
in brain homogenates. In vitro treatment utilizing acel-
lular model for Huntington’s revealed that trehalose,
as well as the oligosaccharide N-acetylgalactosamine
tetramer, the disaccharide maltitol, and the monosac-
charide mannose, each decreased the amount of poly-
glutamine aggregates and/or improved cell survival,
with trehalose proving to be the most effective.
32 A
number of additional sugar molecules showed no ben-
eficial effects, including glucose, N-acetylneuraminic
acid, sucrose, turanose, cellobiose, melibiose, and
melezitose. In a second study, significant improve-
ments in motor function as well as memory perform-
ance were seen in R6/2 mice when treated with a
combination of orally administered trehalose along
with intracranial ventricular injections of neural pro-
genitor cells.
33 The authors of both studies hypothesize
that trehalose may be acting by directly binding to
polyglutamine proteins in the brain and inhibiting
aggregation. Trehalose consumption has also been
shown to be beneficial in a mouse model of tauopathy
with Parkinsonism by improving motor function and
anxiety-related behavior and decreasing tau pathology
through an apparent increase in autophagic
processes.
34
The polysaccharide fucoidan may be another candi-
date for neurodegenerative disease therapies. In an
in vitro model of Parkinson’s disease, fucoidan from
the brown alga Laminaria japonica protected mouse
dopaminergic MN9D cells from 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) toxicity. In an
MPTP-exposed mouse model of Parkinson’s, daily
intraperitoneal injections of Laminaria fucoidan
reducedlocomotordeficits,preventedstriataldepletion
of dopamine, enhanced brain antioxidant activity, and
protected against the loss of dopaminergic neurons in
the substantia nigra.
35 In acutely dissociated rat basal
forebrain neurons from the diagonal band of Broca,
treatment with fucoidan from Fucus vesiculosus
(Bladderwrack) protected cells from A-beta-induced
apoptosis.
36 Preliminary research suggests that fucoi-
dan may also protect against brain damage associated
with ischemic stroke. Compared with control animals,
rats receiving intravenous infusion of Bladderwrack
fucoidanfor7daysfollowingintracerebralhemorrhage
induction showed improved motor function and
memory retention in a passive avoidance test, despite
an increase in hematoma size.
37 The authors hypoth-
esized that these effects were due to fucoidan’s anti-
inflammation or hemodilation activities, although
these possible mechanisms of action were not investi-
gated in this study. Bladderwrack fucoidan, when
administered through intraperitoneal injection, was
also able to attenuate the extent of hypoxia-ischemia-
induced neural damage in the ratcortex,hippocampus,
and striatum.
38
Additional in vitro studies have examined possible
neuroprotective effects of crude plant extracts rich in
complex saccharides (Table 4). Four different polysac-
charide fractions from Nerium indicum (Oleander)
reduced A-beta peptide-induced apoptosis of
primary rat cortical neurons, whereas three of the
extract fractions also improved survival during
serum-deprivation.
39,40 Similar protection against
A-beta toxicity occurred in cultured cortical neurons
treated with various polysaccharide-rich extracts of
Lycium barbarum (Wolfberry).
41–43 Polysaccharide frac-
tions from Wolfberry also reduced the amount of gluta-
mate excitotoxicity and homocysteine-induced cell death
in cortical cultures.
44,45 Finally, an aqueous extract of
Verbena officinalis Linn. (Verbena), containing 30%
w/w carbohydrates, protected primary rat cortical
neurons from the cytotoxic effects of A-beta and dithio-
threitol. The verbena extract had no protective effects
against tunicamycin, hydrogen peroxide, or ultraviolet-
radiation, leading the authors to speculate that com-
ponents of this extract may act as antioxidants and/or
bind directly to putative cell surface receptors that can
detect extracellular A-beta.
46 In this collection of
studies of saccharide-rich extracts, treatments appeared
to improve neuronal survival by either inhibiting intra-
cellular signaling molecules involved in cell death oracti-
vating survival pathways.
Towards a mechanistic understanding of dietary
saccharide-induced neurologic effects
Given the wide range of sugar compositions and struc-
tures of the saccharide compounds discussed in this
review, common mechanisms of action that take
place within the brain following oral consumption
can be difficult to ascertain. Direct effects on the
CNS would have to overcome the significant barriers
of entry for complex carbohydrates that exist
between the gastrointestinal tract and blood stream
Nelson et al. Neurologic effects of exogenous saccharides
Nutritional Neuroscience 2012 VOL. 15 NO. 4 156Table 4 Saccharides and saccharide-rich extracts exert neuroprotective effects in vitro and in vivo
Polysaccharide(s) Source(s) Neuronal preparation Dose Duration Tests performed Significant effects Reference
Trehalose Saccharomyces
cerevisiae
Cultured mouse
neuroblastoma Neuro2a
cells with tNhtt-eGFP
expression (cellular
model of Huntington’s
disease)
50 μM 3 days tNhtt aggregation; MTT assay Decreased tNhtt
aggregation & increased
cell viability
32
3-week-old heterozygous
huntington exon-1-
transgenic mice, strain
R6/2 (bearing 145 CAG
repeats)
2% in
drinking
water
12 weeks Nissl staining and
immunohistochemistry
(ubiquitin); rotarod; foot-
printing; paw clasping
phenotype
Decreased striatal atrophy
and intranuclear
polyglutamine
aggregates in the motor
cortex and striatum;
improved motor
dysfunction, paw
clasping phenotype and
survival
32
3-week-old heterozygous
huntington exon-1-
transgenic mice, strain
R6/2 (bearing 145 CAG
repeats) injected i.c.v.
with murine neural
progenitor cell line C17.2
2% in
drinking
water
10 weeks (cells
injected at week 8)
Immunocytochemistry (Nestin,
MAP-2, ubiquitin); western blot
(expanded polyQ); paw-
clasping phenotype; foot
printing; rotarod; Y-maze
Trehalose alone and in
combination with C17.2
cells decreased
polyglutamine
aggregates in striatum,
increased striatal
volume, extended life
span, delayed onset and
severity of paw clasping,
improved motor function;
combination treatment
was more effective and
also improved memory
performance
33
3-month-old ♂ or 14-month-
old ♀ PK− /−/TauVLW
mice (model of tauopathy
with Parkinsonism)
1% in
drinking
water
3–12 weeks Actimeter; stride length; Y-maze;
immunohistochemistry (TH,
total and phosphorylated tau,
GFAP, A-beta); western blot;
monoamine levels; glutathione
assay
Trehalose improved motor
function and anxiety and
ameliorated tau
pathology and
astrogliosis; reversed
dopaminergic deficits at
10 weeks; autophagy
markers were increased
34
Fucoidan Laminaria
japonica
Cultured mouse
dopaminergic cell line,
MN9D, exposed to the
neurotoxin MPP+
0.01, 0.1, or
1.0 mg/ml
1 hours
pretreatment+ 36
hours cotreatment
with MPP+
LDH activity; MTT assay;
morphology
0.1 and 1.0 mg/ml doses
reversed neuronal injury
caused by MPP +
35
8–10-week-old ♂ C57BL/6
mice injected i.p. with
12.5 or
25 mg/kg
i.p.
18 days (MPTP
injection on day 11)
Locomotor activity; dopamine,
DOPAC and HVA levels in the
striatum; immunohistochemistry
Both doses differentially
rescued locomotor
deficits, prevented
35
Continued
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7Table 4 Continued
Polysaccharide(s) Source(s) Neuronal preparation Dose Duration Tests performed Significant effects Reference
MPTP (model of
Parkinson’s)
and western blot (TH);
oxidative stress and antioxidant
capacity in the substantia nigra
striatal depletion of
dopamine and DOPAC,
protected against the
loss of TH-positive
neurons and lipid
peroxidation, and
enhanced antioxidant
activities in the
substantia nigra
Fucus
vesiculosus
Acutely dissociated
Sprague–Dawley rat
diagonal band of Broca
forebrain neurons
exposed to A-beta;
primary rat basal
forebrain cultures
exposed to A-beta
Ranging from
50 to 1 μM
Active perfusion; 24
hours pretreatment
or 48 hours
cotreatment with
A-beta
Whole-cell patch clamp; MTT and
live/dead assays;
immunohistochemistry (VAchT);
electron microscopy for A-beta
aggregation; DCF
fluorescence; western blot
(cleaved caspase-3; PKC
phosphorylation)
1 μM blocked the A-beta-
induced reduction in
whole-cell currents; 0.1
and 1 μM differentially
protected against A-
beta-induced apoptosis;
10 μM-induced apoptosis
36
7-day-old rats with unilateral
cerebral hypoxia-
ischemia
25–500 mg/
kg i.p.
twice
Immediately before
and after hypoxia
exposure
MPO activity; RT-PCR and
western blot (P-selectin); Nissl
stain of brain slices
25, 50, and 100 mg/kg
doses attenuated brain
damage induced by
hypoxia-ischemia;
>100 mg/kg doses
exhibited toxic side
effects
38
♂ Sprague–Dawley rats with
bolus collagenase-
induced ICH
30 μg/hour
i.v. infusion
7 days, beginning 30
minutes after ICH
MRI; spontaneous circling, ability
to traverse a wooden beam;
forelimb postural reflex;
independent forelimb reaching
and grasping in a staircase
apparatus; passive avoidance
Increased size of
hematoma, but improved
motor function and
memory retention
37
Polysaccharide fractions: J2
(xyloglucan); J3 (1.0 Rha:
1.3 Ara: 4.1 Xyl: 3.6 Gal:
9.1 Glu); J4 (0.3 Rha: 0.8
Ara: 0.1 Xyl: 0.1 Gal)
Nerium indicum Primary rat cortical cultures
exposed to serum-free
media or A-beta peptides
20 or 40 μg/
ml of J2,
J3, or J4
24 hours with serum-
free media; 1 hours
pretreatment+ 24
hours with A-beta
DAPI staining; caspase-3 activity;
western blot (PDK-1 and Akt
phosphorylation)
All fractions and doses
protected against serum-
deprivation-induced and
A-beta-induced
apoptosis
39
Polysaccharide fraction: J6
(1.2 Rha: 2.0 Ara: 1.0 Xyl:
2.0 Gal)
Primary rat cortical cultures
exposed to A-beta
peptides
Ranging from
20 to
500 μg/ml
1 hour
pretreatment+ 24
hours cotreatment
with A-beta
DAPI staining; caspase-3 activity;
LDH activity; western blot
(cleaved caspase-3; p38
MAPK and Akt; JNK, MAPK
and Akt phosphorylation)
100, 250, or 500 μg/ml
doses protected against
A-beta-induced
apoptosis; reduced
cytotoxicity
40
Polysaccharide fraction: LBA
(6.2% w/w protein, 61
neutral sugars; 35.1 M%
Ara, 10.0 Rha, 4.0 Xyl, 1.3
GluAc, 23.9 GalAc, 0.8
Man, 16.0 Gal, 8.9 Glu)
Lycium
barbarum
Primary rat cortical cultures
exposed to A-beta
peptides
Ranging from
0.0001 to
100 μg/ml
1 hour
pretreatment+ 24
hours cotreatment
with A-beta; 1 hour
pretreatment only
(washout)
DAPI staining; morphology;
caspase-3 activity; LDH
activity; western blot (cleaved
caspase-3; JNK and C-Jun
phosphorylation)
0.1, 1, 10, or 100 μg/ml
differentially protected
against A-beta-induced
apoptosis
42
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8Table 4 Continued
Polysaccharide(s) Source(s) Neuronal preparation Dose Duration Tests performed Significant effects Reference
Primary rat cortical cultures
exposed to glutamate
Ranging from
0.1 to
500 μg/ml
24 hours with
glutamate; 1 hour
glutamate+ 23
hours post-treatment
LDH activity; trypan blue stain;
caspase-3 activity; western blot
(JNK phosphorylation);
nitroblue tetrazolium reduction
10, 100, 250, or 500 μg/ml
co- and post-treatment
differentially protected
against glutamate-
induced cell death
44
Primary rat cortical cultures
exposed to Hcy
Ranging from
0.1 to
500 μg/ml
1 hour
pretreatment+ 24
hours Hcy; 1, 2, or 4
hours Hcy+ 23, 22,
or 20 hours post-
treatment
DAPI staining; caspase-3 activity;
LDH activity; western blot
(cleaved caspase-3 and tau;
tau, JNK, GSK-3 beta and ERK
phosphorylation)
100, 250, or 500 μg/ml pre-
and post-treatment
differentially protected
against homocysteine-
induced cell death
45
Polysaccharide fractions: LBB
(4.99%w/w protein, 22
neutral sugars; 32.1 M%
Ara, 31.2 Xyl, 1.4 GluAc,
3.2 GalAc, 2.9 Man, 15.9
Gal, 13.3 Glu); LBB-1
(3.35%w/w protein, 84
neutral sugars; 20.2 M%
Ara, 8.1 Rha, 32.9 Xyl, 8.0
GluAc, 8.2 GalAc, 1.0 Man,
15.6 Gal, 5.3 Glu); LBB-II
(5.82%w/w protein, 75
neutral sugars; 14.1 M%
Ara, 15.8 Rha, 29.1 Xyl, 3.5
GluAc, 22.6 GalAc, 1.0
Man, 8.4 Gal, 5.5 Glu)
Primary rat cortical cultures
exposed to A-beta
peptides
Ranging from
0.1 to
500 μg/ml
1 hour
pretreatment+ 24
hours cotreatment
with A-beta
DAPI staining; caspase-3 activity;
LDH activity; western blot
(cleaved caspase-3; JNK and
Akt phosphorylation)
10, 100, or 500 μg/ml LBB,
10 or 100 μg/ml LBB-I or
LBB-II differentially
protected against A-
beta-induced apoptosis
41
Polysaccharide fractions: LBP
(8.6%w/w protein, 18
neutral sugars; 16.1 M%
Ara, 4.3 Rha, 2.8 Xyl, 14.4
GalAc, 1.5 Man, 12.9 Gal,
47.7 Glu, 0.3 NAcGlu);
LBP-III (6.3%w/w protein,
15 neutral sugars; 6.1 M%
Ara, 1.5 Rha, 92.4 GalAc)
Primary rat cortical cultures
exposed to A-beta
peptides
Ranging from
10 to
500 μg/ml
1 hour
pretreatment+ 24
hours cotreatment
with A-beta
Caspase activity; western blot
(PKR phosphorylation)
100 and 500 μg/ml LBP or
LBP-III protected against
A-beta-induced
apoptosis
43
Aqueous extract: VOA (30%
w/w carb, 2 protein; 33.6
M% GalAc, 21.2 Ara, 18.9
Gal, 10.2 Rha, 4.7 Man, 9.4
Glu, 2 Xyl)
Verbena
officinalis Linn.
Primary rat cortical cultures
exposed to various toxins
(A-beta peptides,
tunicamycin, DTT, UV,
and hydrogen peroxide)
25–150 μg/
ml
1 hour
pretreatment+ 24
hours (A-beta or UV)
or 16 hours (other
toxins)
Caspase-2 and -3 activity;
western blot (PKR and JNK
phosphorylation, caspase-2
and -3); DAPI staining
50, 75, 100, and 150 μg/ml
differentially attenuated
cytotoxic effects of A-
beta and DTT
46
Akt, serine/threonine kinase; Ara, arabinose; DAPI, 4′,6-diamidino-2-phenylindole; DCF, 2,7-dichlorofluorescin; DOPAC, 3,4-dihydroxyphenylacetic acid, DTT, dithiothreitol; ERK, extracellular signal-
regulated kinase; Gal, galactose; GalAc, N-acetylgalactosamine, GFAP, glial fibrillary acidic protein; Glu, glucose; GluAc, N-acetylglucosamine; GSK, glycogen synthase kinase; HVA, homovanillic acid;
Hcy, homocysteine; i.c.v., intracerebroventricular injection; ICH, intracerebral hemorrhage; i.p., intraperitoneal injection; i.v., intravenous injection; JNK, c-Jun N-terminal kinase; LDH, lactate
dehydrogenase; Man, mannose; MAP-2, microtubule-associated protein 2; MAPK, mitogen-activated protein kinase; MPO, myeloperoxidase; MPP+ , 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine; MRI, magnetic resonance imaging; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDK-1, 3-phosphoinositide-dependent kinase 1; PK, parkin; PKC,
protein kinase C; PKR, protein kinase R; Rha, rhamnose; RT-PCR, reverse transcription polymerase chain reaction; TH, tyrosine hydroxylase; tNhtt-eGFP, truncated N-terminal huntington fused to an
enhanced green fluorescent protein; UV, ultraviolet; VAchT, vesicular acetylcholine transporter; Xyl, xylose.
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9and then across the blood–brain barrier. Although
such direct mechanisms cannot be ruled out, it is
perhaps more likely that initial changes are occurring
peripherallyor within the digestive tract itself that ulti-
mately result in cognitive outcomes. To elucidate poss-
ible mechanisms of action that allow ingested
saccharides to affect brain function, one must have
an understanding of how these compounds are pro-
cessed in the gut.
Human enzymes capable of digesting carbohydrates
are largely limited to alpha-amylases that are able to
hydrolyze the glycosidic bonds found in starches and
certain disaccharides such as maltose and sucrose.
Glucose and other monosaccharide subunits are then
released and absorbed into the bloodstream, with
general consensus that the majority of these monosac-
charides travel on to the liver to be used as energy. The
disaccharide trehalose can also be hydrolyzed into its
two glucose subunits by the enzyme trehalase
expressed in cells along the brush border of the small
intestine.
47 Here, we have presented animal and in
vitro studies suggesting trehalose may be a viable
dietary candidate for treatment of neurodegenerative
disorders associated with protein misfolding (tauopa-
thies), although no relevant testing has yet been per-
formed on human subjects. A comparative study of
the effects of trehalose versus glucose in a mouse
model of Huntington’s disease appeared to rule out
the possibility that trehalose provides protective
benefits via an increase in blood glucose levels, since
trehalose was found present within the brain and
glucose administration did not show the same
effects.
32 Additional research is needed to completely
rule out whether changes in blood glucose levels are
occurring following consumption of trehalose or
other naturally derived complex saccharides and
whether these changes are responsible for the observed
alterations in brain function. Recent noteworthy evi-
dence from a human intervention study with the
mixed polysaccharide supplement, Ambrotose
®
complex, demonstrated beneficial effects of acute sac-
charide treatment on brain function, in terms of
memory and cognitively demanding tasks, indepen-
dent of any change in blood glucose response.
14
When consumed, the vast majority of plant-derived,
non-starch complex carbohydrates are considered indi-
gestible by human enzymes and will either pass
through the digestive tract intact or may be broken
down and fermented by species of colonic bacteria.
Many are known to have prebiotic effects, meaning
they can stimulate the growth and/or activity of ben-
eficial bacteria that reside in the digestive tract. For
example, beneficial alterations in intestinal bacteria
have been demonstrated in in vitro and animal
studies of beta-glucan and Ambrotose
® complex.
48,49
New and exciting research has begun to demonstrate
how alterations in gut bacteria can affect animal beha-
viors, such as anxiety and stress-induced changes in
learning and memory, as well as hippocampal
BDNF levels.
50–53 Therefore, it seems plausible that
consumption of complex saccharides may bring
about alterations in intestinal bacteria that result in
cognitive benefits. Complex interactions between the
digestive, immune, and nervous systems may be
responsible for some of the mechanisms by which
this can occur.
Many plant-derived polysaccharides have been
shown to regulate the immune system as they pass
through the intestinal tract.
54 For example, various
beta-glucans demonstrate immune stimulating
effects,
55 whereas saccharides such as those found in
Ambrotose
® complex show anti-inflammatory effects
within the gut.
56 In the study of dietary pectin on
endotoxin-induced social withdrawal presented in
Table 2, the authors suggested that pectin consump-
tion improved intestinal barrier function thereby redu-
cing the entry of LPS into the blood stream and the
subsequent influence of systemic inflammation on
the brain.
19 Once thought to be ‘immune’ to systemic
inflammatory responses, it is now being discovered
that the brain can be influenced by even low
levels of peripherally circulating cytokines.
57
Neuroinflammation can lead to cognitive dysfunction
and is thought to be involved in the etiology of many
neurologic disorders, including Alzheimer’s, multiple
sclerosis, and depression.
58 Therefore, the effects of
saccharide consumption on mood and cognitive func-
tion presented here may conceivably be attributed to
immune signaling. Additional studies are needed,
however, to determine whether immunomodulating
effects of oral polysaccharides are in any way respon-
sible for their influence on neurologic function.
Dietary polysaccharides may also impact brain
function via the digestive tract due to the activation
of parasympathetic nerve fibers, hormonal signaling,
or additional brain–gut axis pathways.
59 For
example, the transport of indigestible fibers through
the colon is largely controlled by the vagus nerve,
which projects directly from the viscera to the brain
stem and can indirectly activate limbic and cortical
regions of the brain involved in regulating mood and
cognition. Vagus nerve stimulation has been proven
as a successful therapy for a wide variety of neurologic
disorders, including epilepsy, depression, and demen-
tia.
60 Interestingly, activation of vagal afferents in
rats has been shown to enhance LTP in the dentate
gyrus
61 and increase norepinephrine levels in the hip-
pocampus,
62 which was one suggested underlying
mechanism for the effects of ingested alpha-glucans
on hippocampal synaptic plasticity.
28,29 Repeating
some of the oral studies presented in this review on
vagotomized animals or human subjects may help
Nelson et al. Neurologic effects of exogenous saccharides
Nutritional Neuroscience 2012 VOL. 15 NO. 4 160elucidate the involvement of the vagus nerve in dietary
saccharide-induced neurologic effects.
Up to this point, no studies have focused on the neu-
roprotective effects of consuming fucoidan or any of
the other polysaccharide-rich plant extracts discussed
in Table 4. Although it seems unlikely that these sys-
temically or centrally applied saccharides are acting
in a similar manner to those administered orally, we
found it pertinent to include them as part of our
review. Often, neuroprotective compounds are first
tested in vitro before going on to show benefits follow-
ing oral administration. Heparin-derived, low-molecu-
lar weight glycosaminoglycans, which are mixtures of
polysulfated oligosaccharides, have indeed shown neu-
roprotective effects both in vitro and in animal
studies.
63 Interestingly, some evidence exists that such
compounds may pass through the blood–brain
barrier when administered peripherally. Del Bigio
et al.
37 speculated that systemically applied fucoidan,
a sulfated heteropolysaccharide, may provide protec-
tion against stroke-induced neurologic damage in
part through its anti-inflammatory effects, which
have been observed following fucoidan ingestion in
animal studies.
54 Future research is needed to
explore whether fucoidan and other natural sulfated
sugar molecules can provide neuroprotective and
other cognitive benefits following oral administration.
Conclusion
There is growing evidence that naturally derived sac-
charides have beneficial effects on brain function,
demonstrated as both cellular and functional effects
in terms of neuroprotection and improvements in cog-
nition and mood. The purpose of this review was to
consolidate studies on the brain-specific effects of
these sugar compounds to help foster research in the
area of natural complex carbohydrates and neurologic
function. At present, an understanding of the efficacy
and mechanisms of action for specific saccharides and
saccharide-rich extracts is limited. The most promising
human clinical research indicates that supplemen-
tation with a blend of plant polysaccharides can have
beneficial effects on brain function related to cognitive
performance and mood. In animals, various alpha-
glucans have shown the most significant effects on be-
havior and synaptic plasticity, whereas trehalose shows
significant promise for neuroprotective benefits.
Encouragingly, the general safety profiles of many of
these dietary polysaccharides for human consumption
are positive, with few reported adverse side effects.
54
Before recommendations can be made regarding
their specific beneficial, preventative, or therapeutic
applications, more robust well-controlled clinical
trials are needed. Additional basic research is alsowar-
ranted to better understand the range of effects of
dietary glycans on brain function and behavior and
to help elucidate the mechanisms behind which they
may be occurring.
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